gavel-istock-508411976_andreypopov
AndreyPopov / iStockphoto.com
18 May 2017Americas

ResMed seeks to dismiss ITC investigation, but plans to refile

Medical device company ResMed has filed a motion to dismiss its International Trade Commission (ITC) complaint against New Zealand-based Fisher & Paykel.

Fisher & Paykel was under ITC investigation for the import of sleep-disordered breathing treatment mask systems.

However, ResMed has now revealed plans to refile its complaint and will incorporate additional evidence generated since the original complaint was filed.

ResMed said in a  press release, issued yesterday, that it believes that refiling the case will make the case even stronger.

It added: “We're committed to protecting our innovation, which is why we've engaged in global legal proceedings with Fisher & Paykel.”

The ITC  announced in September last year that it would institute an investigation based on a complaint filed by ResMed in August the same year.

The complaint alleged violations of the Tariff Act 1930 in the importation into the US and sale of the masks that infringe some of ResMed’s patents.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.


More on this story

Americas
2 October 2018   The US International Trade Commission yesterday announced that it will launch a patent infringement investigation into medical device maker Fisher & Paykel Healthcare, based in New Zealand.
Americas
12 September 2018   Medical device maker Fisher & Paykel Healthcare filed a complaint with the US International Trade Commission yesterday against rival ResMed.

More on this story

Americas
2 October 2018   The US International Trade Commission yesterday announced that it will launch a patent infringement investigation into medical device maker Fisher & Paykel Healthcare, based in New Zealand.
Americas
12 September 2018   Medical device maker Fisher & Paykel Healthcare filed a complaint with the US International Trade Commission yesterday against rival ResMed.